368 related articles for article (PubMed ID: 15215814)
1. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
Napoli C; Sica V; de Nigris F; Pignalosa O; Condorelli M; Ignarro LJ; Liguori A
Am Heart J; 2004 Jul; 148(1):e5. PubMed ID: 15215814
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.
Napoli C; Bruzzese G; Ignarro LJ; Crimi E; de Nigris F; Williams-Ignarro S; Libardi S; Sommese L; Fiorito C; Mancini FP; Cacciatore F; Liguori A
Am Heart J; 2008 Dec; 156(6):1154.e1-8. PubMed ID: 19033012
[TBL] [Abstract][Full Text] [Related]
3. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
[TBL] [Abstract][Full Text] [Related]
4. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
de Nigris F; D'Armiento FP; Somma P; Casini A; Andreini I; Sarlo F; Mansueto G; De Rosa G; Bonaduce D; Condorelli M; Napoli C
Int J Cardiol; 2001 Dec; 81(2-3):107-15; discusssion 115-6. PubMed ID: 11744122
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
García-Estañ J; Ortiz MC; O'Valle F; Alcaraz A; Navarro EG; Vargas F; Evangelista S; Atucha NM
Clin Sci (Lond); 2006 Feb; 110(2):227-33. PubMed ID: 16197366
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.
Silva PS; Fontana V; Palei ACT; Sertório JTC; Biagi C; Tanus-Santos JE
Eur J Clin Pharmacol; 2011 Apr; 67(4):365-370. PubMed ID: 21305271
[TBL] [Abstract][Full Text] [Related]
7. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients.
Yavuz D; Koç M; Toprak A; Akpinar I; Velioğlu A; Deyneli O; Haklar G; Akalin S
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):197-203. PubMed ID: 14608527
[TBL] [Abstract][Full Text] [Related]
8. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients.
Cacciatore F; Bruzzese G; Vitale DF; Liguori A; de Nigris F; Fiorito C; Infante T; Donatelli F; Minucci PB; Ignarro LJ; Napoli C
Eur J Clin Pharmacol; 2011 Sep; 67(9):877-83. PubMed ID: 21445638
[TBL] [Abstract][Full Text] [Related]
9. Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice.
Liu YH; Liu LY; Wu JX; Chen SX; Sun YX
J Cardiovasc Pharmacol; 2006 Jan; 47(1):82-8. PubMed ID: 16424790
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
Chen SX; Song T; Zhou SH; Liu YH; Wu SJ; Liu LY
Eur J Pharmacol; 2008 Apr; 584(2-3):368-75. PubMed ID: 18334254
[TBL] [Abstract][Full Text] [Related]
11. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X.
Chen JW; Hsu NW; Wu TC; Lin SJ; Chang MS
Am J Cardiol; 2002 Nov; 90(9):974-82. PubMed ID: 12398965
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibition restores the vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously Hypertensive rats.
Lewis SJ; Hashmi-Hill MP; Owen JR; Sandock K; Robertson TP; Bates JN
Vascul Pharmacol; 2006 Jun; 44(6):491-507. PubMed ID: 16713366
[TBL] [Abstract][Full Text] [Related]
13. Effect of captopril and enalapril on endothelial function in hypertensive patients.
Creager MA; Roddy MA
Hypertension; 1994 Oct; 24(4):499-505. PubMed ID: 8088918
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
[TBL] [Abstract][Full Text] [Related]
15. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure.
Buikema H; Monnink SH; Tio RA; Crijns HJ; de Zeeuw D; van Gilst WH
Br J Pharmacol; 2000 Aug; 130(8):1999-2007. PubMed ID: 10952693
[TBL] [Abstract][Full Text] [Related]
16. Contribution of captopril thiol group to the prevention of spontaneous hypertension.
Pechánová O
Physiol Res; 2007; 56 Suppl 2():S41-S48. PubMed ID: 17824808
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
[TBL] [Abstract][Full Text] [Related]
18. Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat.
Khattab MM; Mostafa A; Al-Shabanah O
Kidney Blood Press Res; 2005; 28(4):243-50. PubMed ID: 16220007
[TBL] [Abstract][Full Text] [Related]
19. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress.
Scribner AW; Loscalzo J; Napoli C
Eur J Pharmacol; 2003 Dec; 482(1-3):95-9. PubMed ID: 14660009
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition.
Bucci M; Vellecco V; Cantalupo A; Brancaleone V; Zhou Z; Evangelista S; Calderone V; Papapetropoulos A; Cirino G
Cardiovasc Res; 2014 Apr; 102(1):138-47. PubMed ID: 24501330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
